 |
市場調查報告書
商品編碼
1550582
GLP-1 受體促效劑市場：依藥物類別、給藥途徑、應用、通路及地區GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
預計2024年全球GLP-1受體促效劑市場規模為251億美元，預估2031年將達557億美元，2024年至2031年複合年成長率為12.1%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 251億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024年至2031年 |
| 預測 2024-2031 年複合年成長率： | 12.10% | 2031年價值預測 | 557億美元 |
GLP-1受體促效劑是一類重要的治療第二型糖尿病的抗糖尿病藥物。它們模仿內源性Glucagon-Like Peptide-1(GLP-1) 的作用，GLP-1肽激素，可刺激胰島素分泌並以葡萄糖依賴性方式抑制升糖素分泌。這些藥物透過結合並激活 GLP-1 受體，誘導糖尿病患者胰島素分泌並抑制升糖素分泌，從而抑制食慾並促進減肥。與其他藥物類別相比，卓越的血糖控制效果和低低血糖風險使其成為有吸引力的選擇，並正在推動市場成長。
市場動態：
全球GLP-1受體促效劑市場的成長是由全球糖尿病盛行率不斷上升以及GLP-1受體促效劑卓越的治療功效所推動的。肥胖的增加會增加罹患第 2 型糖尿病的風險，從而增加對更有效治療方法的需求。然而，高昂的開發成本和嚴格的監管核准可能會阻礙市場成長。具有改進配方、靈活劑量選擇、更長作用持續時間、多藥組合等特點的新產品的推出可能會帶來成長機會。製造商正在投資研發來開發口服製劑，以擴大臨床適應症並提高患者便利性。
本研究的主要特點
本報告對全球GLP-1受體促效劑市場進行了深入分析，包括以2023年為基準年的預測期（2024-2031）的市場規模（十億美元）和年複合成長率（CAGR%）已發布。
它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、業務績效和策略等參數對全球 GLP-1 受體促效劑市場的主要企業進行了分析。
本研究涵蓋的主要企業包括諾和諾德公司、禮來公司和賽諾菲。
該報告的見解將幫助負責人和公司經營團隊就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球 GLP-1 受體促效劑市場報告針對該行業的各個相關人員相關者，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
透過用於分析全球 GLP-1 受體促效劑市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章 市場動態、法規與趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管場景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
第4章全球 GLP-1 受體促效劑市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第5章全球 GLP-1 受體促效劑市場，依藥物類別，2019-2031
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- albiglutide
- Semaglutide
第6章全球GLP-1 受體促效劑市場，依給藥途徑，2019-2031
- 胃腸外的
- 口服
第7章全球GLP-1 受體促效劑市場，依應用分類，2019-2031
- 2型糖尿病
- 肥胖
- 肝硬化
- 非酒精性脂肪性肝炎
- 其他
第8章全球GLP-1受體促效劑市場，依通路，2019-2031
- 醫院藥房
- 零售藥房
- 網路藥房
第9章全球GLP-1受體促效劑市場，按地區，2019-2031
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第10章競爭格局
- 公司簡介
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
第11章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第12章參考文獻與調查方法
- 參考
- 調查方法
Global GLP-1 receptor agonist market is estimated to be valued at USD 25.10 Bn in 2024 and is expected to reach USD 55.70 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 25.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 12.10% | 2031 Value Projection: | US$ 55.70 Bn |
GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.
Market Dynamics:
Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.
Key Features of the Study:
This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global GLP-1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation-
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- Parenteral
- Oral
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Cassiopea
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global GLP-1 Receptor Agonist Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global GLP-1 Receptor Agonist Market, By Drug Class, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Exenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Liraglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Dulaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Lixisenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Albiglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Semaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global GLP-1 Receptor Agonist Market, By Route of Administration, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global GLP-1 Receptor Agonist Market, By Application, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Type 2 Diabetes Mellitus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Obesity
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Liver Cirrhosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Non-alcoholic Steatohepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
9. Global GLP-1 Receptor Agonist Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Eli Lilly and Company
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
GLP-1受體激動劑市場機會、成長動力、產業趨勢分析及2024年至2032年預測
GLP-1受體促效劑市場規模、佔有率和趨勢分析報告：按產品、按應用、按給藥途徑、按地區和細分市場預測，2025-2030年
GLP-1 受體促效劑市場：按藥物類型、給藥途徑、分銷管道和應用分類 - 全球預測 2025-2030
GLP-1受體促效劑市場規模、佔有率和趨勢分析報告：按產品、按應用、途徑、按地區和細分市場預測，2024-2030年
GLP-1受體激動劑市場 - 按藥物類別（Semaglutide、Dulaglutide、Liraglutide、Exenatide），按給藥途徑（腸外），按應用（2型糖尿病、肥胖症），按分銷（醫院、零售），全球預測，2023 - 2032